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Steady-state mRNA levels and protein synthesis of collagen type V[ were determined after stimulation o f  human dermal flbroblasts with 
translbrming growth factor-p (TGFp). While there was a 227% increase in the 0t3(Vl) subunit InRNA at maximal TGF-/~ concentration, ,',l(VI) 
and a2(VI) subunit mRNA lcvcis remained unchanged. Concomitantly collagen type VI immune.reactive material increased up to 172% ofcontrols 
in cell culture medium and cell layer extracts. Regulation of 0t3(VI) gene expression istherefore critical for the control ofcollagen type VI synthesis 
and determines the deposition of collagen type VI heterotrimeric molecules. 
1. INTRODUCTION 
Collagen type YI is a structural component within the 
interstitial connective tissue of almost every organ (for 
review see [1]). Its molecular structure has been deduced 
from electron microscopy studies as well as from eDNA 
and protein sequencing [2]. Collagen type VI is com- 
posed of three individual 0c chains, 0tl(VI), ~2(VI) (both 
of 140 kDa) and 0z3(VI) (340 kDa), with each being the 
product of a distinct single-copy gene. It is distinguished 
from other collagen types by a particularly short seg- 
ment involved in triple helix formation and large globu- 
lar domains at both ends [2]. The supramolecular s- 
sembly of collagen type VI represents a major part of 
the microfibriilar network within extrac~.llular matrices 
[3,4]. Such microfibrils are often located around larger 
anatomical structures such as nerves, blood vessels and 
collagen fibers [5]. Increased amounts of collagen type 
VI have been observed in certain pathological condi- 
tions with disturbed connective tissue composition, such 
as multiple fibromatosis with articular dysplasia [6], 
neurofibromatosis [7] and keloids [8]. At present, how- 
ever, little is known about the regulation of collagen 
type VI biosynthesis. 
Collagen type VI is abundantly expressed incultured 
hunaan fibroblasts [9,10] and controlled by regulatory 
mechanisms independent from those regulating the in- 
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terstitial collagen types 1 and II1 [11]. We have shown 
previously that interferon-?' selectively reduces the 
mRNA expression of only one subunit of collagen type 
VI, the cx3(Vl) chain. It was also demonstrated that this 
is sufficient to diminish the secretion and deposition of 
newly synthesized heterotrimeric mol~ules [12]. 
We now report on the effect of a potent collagen 
synthesis-inducing cytokine, transforming rowth fac- 
tor-fl (TGF-fl) [13]; on specific mRNA and protein ex- 
pression of all three collagen type VI chains. Our results 
indicate that the gene encoding the cz3(VI) chain is the 
only target for this cytokine. This suggests that mecha- 
nisms regulating the synthesis of 0t3(Vl) chain are cru- 
cial for the production • of the entire• collagen type VI 
molecule. 
2. MATERIALS AND METHODS 
2. !. Ceil cultures and TGF~ treatment 
Human skin fibroblasts were obtained by cxplautation fskin biop- 
sies as described elsewhere [14], and cultured in Dulbec, o's modified 
Eagle's medium (DMEM), supplemented with 10% fetal calf serum, 
50/.tg/ml ascorbate, 300/.,gtml #atamine, 50/ugtml streptomycin a d 
400 U/ml penicillin. Confluent fibroblast cultures between passages 4 
and 9 were used for the following experiments. 
Cells were washed with phosphate-buffered saline and then inca- 
bated for 24 or 48 h in fresh mtMiam containing TGF-fl (Paesei, 
Frankfurt, Germany) at concentrations rauging from 0 to 5 ng/ml. 
Medium was renewed after 24 h. For all experiments a separate set 
of culture dishes treated in the same manner was used to determine 
cell numbers (5.6--7.5 × 10 ~ cells/dish). 
2.2. Determination f mRNA levels 
Total RNA was isolated from TOF.~-treated and untreated flbro- 
blasts following established procedures lib']. Briefly, cells w~re col- 
lected in 4 M guanidilm isothiocyanate followed by ultr~t..eentrifuga- 
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lion over a 5.7 M CsCI cushion. The resulting pellet was dissolved in 
water, extracted with phenol/chloroform, ethanol precipitated and 
re-dissolved in 10 mM Tris-HCl, I mM EDTA, pH 7, The amount of 
total RNA was determined photometrically at 260 nm. Northern blot 
and dot blot analysis using specific •eDNA probes for the collagen 
chains, 0d(l), ell(V!), a2(Vl) and a3(Vl), was carried out as described 
previously [12]. For the determination ffl.tubulin mRNA a 264 bp 
eDNA fragment of the D.I clone [16] was used. 
2.3. Determination f protein ~),ntheais 
Control and TGF-fl-treated fibroblasts were pulse labeled using 500 
/aCi/dish of [~H]proline (Amersham, 3300 Braunschweig, Germany) in 
serum-free, otherwise identical medium during the final 24 h of incu- 
bation. Culture media were collected on ice and frozen immediately 
at -20"C alter addition of protease inhibitol~ (0.5 mM phenylmethane 
sulfonyl fluoride, 5 mM N-ethylmal¢imide, 1 mM EDTA), Cell mono- 
layers were subjected to extraction and analyzed by imm uno-dot bind- 
ing assay as previously described [12] using antibodies raised against 
collagen VI [41. Incorporation of [aH]proline in newly synthesized 
material was determined by measuring the radioactivity of ethanol- 
precipitated proteins from the culture medium and the cell layer ex- 
tracts. Labeled culture medium was treated with p~psin (0.1% in 0.5 
M acetic acid, 6 h at 4°C) and analyzed by SDS-PAGE on 10-20% 
acrylamide gradient gels after reduction with fl-mercaptoethanol. The 
gels were processed for fluorography as described previously [12] and 
exposed to X-ray films. 
3. RESULTS 
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Fig. 2. TGF.fl dose-dependent mRNA-levels of collagen type VI sub- 
units. Confluent human dermal fibroblasts were incubated with vari- 
• ous concentrations of TGF-fl for 48 h. Total RNA was isolated and 
specific mRNA levels for al(V|) (o), ~2(Vi) (I), and a3(VI) (zx) were 
determined by dot blot analysis as described in section 2. After den- 
sitometri¢ scanning of radiographs, results were calculated as the ,% 
of untreated controls. Results are expressed as means ± $.D. of three 
independent experiments. 
3.1. Collagen type VI mRNA steady-state l vels 
Treatment for 48 h of confluent human dermal fi- 
broblasts with TGF-fl resulted in a selective increase of 
the mRNA coding for the a3(VI) chain of collagen type 
VI as observed by Northern blot analysis (Fig. 1). In 
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contrast, levels of the mRNAs coding for the ~I(VI) and 
~x2(VI) chains were not affected (Fig. 1). The effect of 
TGF.fl on ~3(VI) mRNA was dose-deper.dent, as 
shown by dot blot analysis of specific mRNA levels 
after exposure of the cells to different concentrations of 
TGF-fl (Fig. 2). The maximal increase of0~3(VI) mRNA 
(227%) by TGF-fl (5 ng/ml, 48 h) was comparable to 
that of another collagen chain, cO(l) mRNA (219%) 
under identical conditions (Table I). An incubation pe- 
riod of 24 h with TGF-fl resulted in a similar, but less 
pronounced selective increase of the ~3(VI) and =1(1) 
mRNA levels (Table I). These effects were consistently 
observed in the presence or absence of fetal calf serum 
(not shown). Expression of fl tubulin, an intracelhtlar 
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Fig. 1. Northern blot analysis of collagen type Vl-speeifie mgNAs in 
TGF-fl-treated fibroblasts. Confluent human dermal fibroblasts were 
incubated for 48 h without (A) or with (B) TGF-fl (5 ng/ml). Total 
RNA was separated by gel eleetrophoresis a  described in section 2 
and transferred onto nitroeeilulo~. Filters were hybridized with ~:P- 
labeled eDNA probes pecific for ,a,I (VI), a2(¥1), and a3(V1) chains, 
Yielding signals of the expected sizes [9]. 
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Table I 
Collagen mRNA levels in fibroblasts after TGF-fl treatment 
mRNA analyzed Duration of TGF-fl treatment 
24 h 48 h 
Collagen type 1 el( l) 169 _ 15 219 "k_ 21 
Collagen type Vl al(Vl) 104 "t- 12 96 ~ 17 
Collagen type VI ~2(VI) 98 _.+ 15 109 "J- 14 
Collagen type VI ct3(Vl) 162 ± 19 227 ± 19 
fl-Tubulin I10 _ 16 114 +_ 18 
Cells were treated for 24 and 48 h with TGF-fl (5 ng/ml), Specific 
mRNA lcvel~ were determined by dot blot analysis and are expressed 
as the % of control values obtained with untreated cells (=100%). 
Results are expressed as mean ± S.D. of three independent 
experiments. 
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Table l I 1 
Protein synthesis inTGF-fl-treated human skin fibroblast cultures 
TGF-~ (~H]Prolin¢ incorporation Collagen q/pc VI (%) 
(ng/ml) in 
Total Medium Cell layer 
(cpm/103 (%) (%) 
cells) 
Medium Cell layer 
0 3,648 +__ 196 62 38 100 100 
0,5 5,200"__ 801 56 44 147 . 132 
5 5,177 + 89"1 46 54 177 168 
Human skin fibroblasts were incubated for 48 h with the indicated 
concentrations of TGF-,d. Incorporation o1" [~H]proline was deter- 
mined by measuring the radioactivity ofethanol.precipitable material 
in culture media nd ¢¢11 layers. Collagen type VI production was 
evaluated by immune-dot binding assay [11] and the results were 
expressed in % compared tountrealed cells et at 100%. All values are 
the mean of three separate experiments. 
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Fig, 3. Ele, ctrophoretic analysis of labeled culture medium from con- 
trol and TGF-fl-treated fibroblasts. Samples were used without (lanes 
i, 3 and 5) or after (lanes 2, 4 and 6) pepsin treatment. (Lanes i and 
2) control fibroblasts; (lanes 3and 4) 0.5 ng/mi TGF-fl-tmated libro- 
blasts; (lanes 5and 6) 5 n~ml TGF-fl-treated fibroblasts. Open arrow- 
heads denote the position ofcollagen type 1 chains. Clerk! arrowheads 
denote the position o£ pepfin-resistant collagen type VI chains (from 
top to bottom, , I(VI), ~2(Vi) and ~3(VI) chains). 
constitutive protein, was only slightly increased to 121% 
at the maximal TGF-fl concentration, indicating that 
the TGF-/~-induced changes of collagen synthesis are 
specific (Table 1). 
3.2. Collagen type VI and proteflt synthesis 
After incubation of fibroblasts with TGF-fl (5 ng/ml), 
total protein synthesis estimated by [3H]proline incor- 
poration increased up to 142% of untreated cells (Table 
II). In addition there was a shift • in the distribution of 
radiolabeled material between culture medium and cell 
layers (Table II) indicating that TGF-fl-treated cells in- 
corporate more of the newly synthesized material into 
the cell layer than untreated cells. 
Immunological analysis also showed a maximal in- 
crease of 172% for collagen VI after TGF-fl treatment 
• (Table I1). This increase was observed for both the ma- 
terial secreted into the culture medium and that depos- 
ited into the cell layer. An increase in type VI collagen 
production was also demonstrated by electrophoresis 
after metabolic labeling of cell culture medium. Pepsin 
digestion followed by reduction showed the characteris- 
tic triplet bands of ~ collagen VI in the control medium 
and a distinct increase in all three bands after TGF-fl 
treatment (Fig. 3). This strongly indicates that TGF-fl 
causes increased production of collagen VI containing 
all three chains in stoichiometric proportions [9]. 
4, DISCUSSION 
Many studies have shown that TGF-fl up-regulates 
the expression of the fibril-forming collagen types, I and 
IlI, of fibronectin, proteoglyeans and several collagen- 
binding intvgrin receptors [13,17-20]. In addition it low- 
ers the production of matrix metailoprotoases and in- 
creases that of their inhibitors [21 ]. These effects of the 
cytokine point to a central role in the regulation of 
extracellular matrix deposition by increasing synthesis 
and interfering with the catabolic mechanisms [13]. Our 
data add collagen type VI to the list of  matrix compo- 
nents up-regulated by TGF-fl even though only the 
a3(VI) chain seems to be involved at the mRNA level. 
For fibroblasts grown at different cell densities or in a 
collagen gel it was previously shown that the synthesis 
of collagen VI is independently regulated from that of 
collagen types I and IlI [11]. TGF-fl apparently imposes 
a new regulatory mechanism and forces the synthesis of 
all the collagens examined so tar in fibroblasts in the 
same direction. Presumably this occurs by the induction 
of trans-acting factors which are Still not well defined 
[22]. A related phenomenon was observed in fibroblasts 
treated with interferon-z [12] which reduces similarly 
expression of collagen types I, Ill and VI, in the latter 
ease by a selective down-regulation of ~,3(VI)mRNA. 
/'his suggests that the human a3(Vl) chain gene. which 
is located on chromosome 2q37 [23], plays a crucial 
regulatory function in collagen type VI synthesis. The 
al(Vl) and a2(Vl) chain genes are syntenic on chromo- 
some 21q23 and apparently co-regulated in fibroblasts 
and some tumor ~lls [9AI]. Their expression is not 
affected by TGF-fl. as shown hero and by interferon:), 
[12]. 
Steady-state mRNA levels of ~I(VI), cz2(Vl) and 
~3(VI) stiow an approximate 1:1:1 ratio in cultured fi- 
broblasts [9,11]. The down-regulation ofcz3(Vl) mRNA 
by interferon-~, causes a reduced synthesis and deposi- 
tion of collagen type VI [12], which is in agreement with 
structural predictions [24] that only trimeric molecules 
possessing all three chains are the genuine and most 
stable assembly products. Even though those chains 
produced in excess can be secreted, they are not prop- 
erly stabilized against pepsin treatment and not depos- 
ited in the cell matrix [12]. The steady-state mRNA 
81 
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levels in fibroblasts may° however, not necessarily re- 
flect the levels of newly synthesized chains. The data 
shown here suggest a more efficient translation of 
gl(Vl) and ~2(VI) compared to ct3(V1) chains which, 
when compensated by a TGF-fl-mediated increase in 
cx3(Vl) mRNA, allows for the increased production of 
stable collagen type VI molecules. This rescues the sur- 
plus of ~tl(VI) and ~2(VI) chains in a pepsin-stable 
form, as demonstrated in Fig. 3. There is also some 
evidence that similar processes may occur in situ. A 
strong induction of ~3(VI) mRNA is seen during early 
phases of wound healing, which declines at later stages 
before the increased expression of 0fl(VI) and cz2(VI) 
mRNA [25]. A spatial and temporal co-expression was 
also observed for TGF-fl and collagen type VI in human 
keioids [8]. Our data therefore suggest a mechanism 
which may be of relevance for connective tissue deposi- 
tion during repair processes and fibrosis. 
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